Key Points
- Insider sale: Johanna Mercier sold 3,000 GILD shares on December 15 at an average price of $122.00 for $366,000, trimming her position by 2.75% to 106,221 shares (≈$12.96M).
- Pattern of selling: Mercier also sold 28,000 shares on November 17 at $125.86 ($3.524M) and 3,000 shares on October 15 at $118.08 ($354,240), suggesting continued insider dispositions over recent months.
- Company context: Gilead recently beat quarterly EPS and revenue, issued FY2025 EPS guidance of 8.05–8.25, and pays a $0.79 quarterly dividend (2.7% yield) while holding a consensus "Moderate Buy" rating and $131.54 price target.
Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) insider Johanna Mercier sold 3,000 shares of the company's stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $122.00, for a total transaction of $366,000.00. Following the completion of the sale, the insider directly owned 106,221 shares in the company, valued at approximately $12,958,962. The trade was a 2.75% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Johanna Mercier also recently made the following trade(s):
- On Monday, November 17th, Johanna Mercier sold 28,000 shares of Gilead Sciences stock. The shares were sold at an average price of $125.86, for a total value of $3,524,080.00.
- On Wednesday, October 15th, Johanna Mercier sold 3,000 shares of Gilead Sciences stock. The stock was sold at an average price of $118.08, for a total value of $354,240.00.
Gilead Sciences Price Performance
Gilead Sciences stock opened at $118.78 on Wednesday. The business has a 50 day simple moving average of $122.06 and a 200 day simple moving average of $115.93. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.45 and a quick ratio of 1.31. The company has a market capitalization of $147.37 billion, a PE ratio of 18.42, a price-to-earnings-growth ratio of 0.66 and a beta of 0.32. Gilead Sciences, Inc. has a one year low of $88.57 and a one year high of $128.70.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.16 by $0.31. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The company had revenue of $7.77 billion during the quarter, compared to analysts' expectations of $7.42 billion. During the same period last year, the business earned $2.02 earnings per share. The business's revenue was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, sell-side analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.
Gilead Sciences Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th will be paid a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 2.7%. The ex-dividend date of this dividend is Monday, December 15th. Gilead Sciences's dividend payout ratio is currently 48.99%.
Analyst Upgrades and Downgrades
GILD has been the subject of a number of research analyst reports. Wells Fargo & Company lifted their target price on shares of Gilead Sciences from $145.00 to $150.00 and gave the company an "overweight" rating in a research note on Wednesday, December 10th. Sanford C. Bernstein reiterated an "outperform" rating on shares of Gilead Sciences in a research report on Monday, November 3rd. Cantor Fitzgerald restated an "overweight" rating and set a $135.00 target price on shares of Gilead Sciences in a report on Friday, October 31st. HSBC lifted their price target on Gilead Sciences from $110.00 to $133.00 and gave the company a "hold" rating in a report on Wednesday, December 10th. Finally, JPMorgan Chase & Co. upped their target price on shares of Gilead Sciences from $145.00 to $150.00 and gave the stock an "overweight" rating in a research report on Friday, October 31st. Two analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, Gilead Sciences currently has a consensus rating of "Moderate Buy" and a consensus price target of $131.54.
View Our Latest Stock Report on GILD
Hedge Funds Weigh In On Gilead Sciences
A number of hedge funds and other institutional investors have recently bought and sold shares of GILD. GoalVest Advisory LLC lifted its stake in shares of Gilead Sciences by 7,566.7% in the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 227 shares during the period. Corundum Trust Company INC acquired a new position in Gilead Sciences in the third quarter valued at about $26,000. Activest Wealth Management boosted its holdings in Gilead Sciences by 2,837.5% during the first quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company's stock worth $26,000 after buying an additional 227 shares during the last quarter. Harbor Asset Planning Inc. acquired a new position in shares of Gilead Sciences during the 2nd quarter worth about $27,000. Finally, Howard Hughes Medical Institute bought a new stake in shares of Gilead Sciences in the 2nd quarter valued at about $30,000. 83.67% of the stock is owned by institutional investors.
Gilead Sciences Company Profile
(
Get Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
